The role of surgery in the management and prognosis of limited-stage Ⅱ small cell lung cancer
10.3760/cma.j.issn.1001-4497.2014.09.002
- VernacularTitle:局限Ⅱ期小细胞肺癌的外科疗效分析
- Author:
Mingran XIE
;
Shibin XU
;
Jin GAO
;
Xinyu MEI
;
Tian LI
;
Xiaohui SUN
;
Dongchun MA
- Publication Type:Journal Article
- Keywords:
Carcinoma,small-cell lung;
Pneumonectomy;
Chemotherapy;
Radiotherapy;
Prognosis
- From:
Chinese Journal of Thoracic and Cardiovascular Surgery
2014;30(9):517-520
- CountryChina
- Language:Chinese
-
Abstract:
Objective The aim of this retrospective study was to analyze the role of surgery in the management of limited-stage-Ⅱ small cell lung cancer.Methods A retrospective review of 82 patients with limited-stage Ⅱ small cell lung cancer between January 2001 and December 2009 was performed.The prognostic impact of different therapy and the clinicopathologic factors were analyzed.Using SPSS 16.0 statistical software for data analysis.Log-rank test for the difference of survivale rate.Using the Cox model for muliti-factor survival analysis.Chi-square test for local recurrence and distant metastasis rate.Results The overall median survival time and the 1-,3-,and 5-year overall survival rates were 27.0 months,62.1％,35.9％,and 21.0％,respectively.Median survival was 34.0 months in surgical patients vs 16.0 months in nonsurgical patients (P =0.000).Median survival after lobectomy or pneumonectomy was significantly longer than after wedge resection (P =0.048).However,survival after wedge resection was still significantly longer than survival in nonsurgical patients(P =0.024).Survival analysis confirmed that the operation,chemotherapy and radiotherapy were showed to be independent prognostic factors.The local-regional recurrencer rates of lobectomy or pneumonectomy group was lower than wedge resection group(P =0.030).The distant metastasis rates of lobectomy or pneumonectomy group was lower than nonsurgical grou (P =0.021).Conclusion This study suggests that lobectomy or pneumonectomy combined with adjuvant radio-chemotherapy should be recommended for patients with limited-stage Ⅱ small cell lung cancer.
